When it comes to rare diseases, Canada’s healthcare and research systems weren’t built to keep up. That’s where the Canadian Rare Disease Network (CRDN)  steps in—a new initiative working to change the rare disease journey for millions across the country. With over 7,000 known rare diseases affecting more than 3 million people in Canada, patients and families often face long diagnostic delays, limited treatment options, and fragmented care. CRDN was launched in 2024 to connec

Kate Salonga represents PHA Canada at the 2025 PH Professional Network Symposium hosted by the Pulmonary Hypertension Association (US)....

This week, Statistics Canada released the results of their crowdsourced study on the lived experiences of Canadians (and their families...

On September 30, Canadians pause to mark the National Day for Truth and Reconciliation , a time to honour the children, families, and...

At PHA Canada, we’re committed to providing clear, accessible resources to help patients, caregivers, and healthcare professionals better...

The Pulmonary Hypertension Association of Canada (PHA Canada) is proud to announce a new partnership with Vision Quest Communications...

Yesterday, Colin Van De Wetering, a Registered Respiratory Therapist and Certified Respiratory Educator, joined our Monthly Meet-Up to...

For years, PHA Canada has been working to ensure that the drug approval process in Canada meets the needs of our pulmonary hypertension...

The Pulmonary Hypertension Global Patient Survey  (PHGPS), the largest survey to date to explore the perspectives of patients with PH at...

Here are a few things that the Canadian PHriends Facebook group members found make their lives easier. Around the house Air conditioning...

Applications for the Canada Disability Benefit (CDB) open this week. If you're eligible for the Disability Tax Credit and you (and your...

On a beautiful June day filled with sunshine and warmth, our community gathered for a special fundraiser in honour of Andrew Barfoot....

What it is Yutrepia is a new drug: an inhaled form of treprostinil, a prostacyclin analogue. It was just approved by the Food and Drug...

The ZENITH study looked at some of the sickest pulmonary arterial hypertension (PAH) patients—those labelled as functional class 3...

"A person's mental health significantly influences how they experience pain and suffering associated with chronic disease. It's essential...

We asked Liss Cairns, Program Manager at Plan Institute, some questions about the Disability Tax Credit and the new Canada Disability...

Living with a rare disease can feel like walking an unmarked path—isolated, uncertain, and overlooked. For those with pulmonary arterial...

The 2025 BC Medication Coverage Report  is here—and it reveals serious gaps in access to life-saving medications across the province....

There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it...

Tax season is upon us! The pulmonary hypertension community brought two tips to our attention. First, the usual disclaimer: we are not...